Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV

References

• Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Front Endocrinol (Lausanne). 2018; 9:705.
   PubMed Web of Science ®Google Scholar
• Mankal PK, Kotler DP. From wasting to obesity, changes in nutritional concerns in HIV/AIDS. Endocrinol Metab Clin North Am. 2014; 43(3):647–663.
   Web of Science ®Google Scholar
• Bogner JR, Vielhauer V, Beckmann RA, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001; 27(3):237–244.
   PubMed Web of Science ®Google Scholar
• Falutz J. Therapy insight: body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Pract Endocrinol Metab. 2007; 3(9):651–661.
   Google Scholar
• McComsey GA, Moser C, Currier J, et al. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis. 2016; 62(7):853–862.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Fiorillo S, Masawi F, et al. Antiretroviral initiation is associated with increased skeletal muscle area and fat content. Aids 2017; 31(13):1831–1838.
   Web of Science ®Google Scholar
• Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. Aids 2003; 17(7):971–979.
   PubMed Web of Science ®Google Scholar
• Debroy P, Lake JE, Moser C, et al. Antiretroviral therapy initiation is associated with decreased visceral and subcutaneous adipose tissue density in people living with HIV. Clin Infect Dis [published ahead of print]. 2020. DOI:10.1093/cid/ciaa196.
   Web of Science ®Google Scholar
• Goodpaster BH, Carlson CL, Visser M, et al. Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. J Appl Physiol (Bethesda, MD 1985). 2001; 90(6):2157–2165.
   PubMed Web of Science ®Google Scholar
• Scott D, Shore-Lorenti C, McMillan LB, et al. Calf muscle density is independently associated with physical function in overweight and obese older adults. J Musculoskelet Neuronal Interact. 2018; 18(1):9–17.
   PubMed Web of Science ®Google Scholar
• Anderson DE, Quinn E, Parker E, et al. Associations of computed tomography-based trunk muscle size and density with balance and falls in older adults. J Gerontol A Biol Sci Med Sci. 2016; 71(6):811–816.
   PubMed Web of Science ®Google Scholar
• Lake JE, Debroy P, Ng D, et al. Associations between subcutaneous fat density and systemic inflammation differ by HIV serostatus and are independent of fat quantity. Eur J Endocrinol/Eur Federation Endocr Soc. 2019; 181(4):451–459.
   Web of Science ®Google Scholar
• Guaraldi G, Orlando G, Squillace N, et al. Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy. HIV Clin Trials 2006; 7(3):97–106.
   PubMed Web of Science ®Google Scholar
• Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994; 49(2):M85–M94.
   PubMedGoogle Scholar
• Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol (Bethesda, MD 1985). 2000; 89(1):104–110.
   PubMed Web of Science ®Google Scholar
• Schafer AL, Vittinghoff E, Lang TF, et al. Fat infiltration of muscle, diabetes, and clinical fracture risk in older adults. J Clin Endocrinol Metab. 2010; 95(11):E368–E372.
   Web of Science ®Google Scholar
• Goodpaster BH, Thaete FL, Kelley DE. Composition of skeletal muscle evaluated with computed tomography. Ann NY Acad Sci. 2000; 904:18–24.
   PubMed Web of Science ®Google Scholar
• Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. J Clin Epidemiol. 2009; 62(2):143–148.
   PubMed Web of Science ®Google Scholar
• Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27(4):299–309.
   PubMed Web of Science ®Google Scholar
• Srinivasa S, Grinspoon SK. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. Eur J Endocrinol. 2014; 170(5):R185–R202.
   PubMed Web of Science ®Google Scholar
• Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. Aids 1999; 13(18):2493–2505.
   PubMed Web of Science ®Google Scholar
• Bhagwat P, Ofotokun I, McComsey GA, et al. Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race. Open Forum Infect Dis. 2018; 5(11):ofy201.
   PubMed Web of Science ®Google Scholar
• Lake JE, McComsey GA, Hulgan T, et al. Switch to raltegravir from protease inhibitor or nonnucleoside reverse-transcriptase inhibitor does not reduce visceral fat in human immunodeficiency virus-infected women with central adiposity. Open Forum Infect Dis. 2015; 2(2):ofv059.
   Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis [published ahead of print]. 2019. DOI:10.1093/cid/ciz999.
   Web of Science ®Google Scholar
• Norwood J, Turner M, Bofill C, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017; 76(5):527–531.
   PubMed Web of Science ®Google Scholar
• Kerchberger AM, Sheth AN, Angert CD, et al. Weight gain associated with integrase stand transfer inhibitor use in women. Clin Infect Dis. 2020; 71(3):593–600.
   Web of Science ®Google Scholar
• Calza L, Danese I, Colangeli V, et al. Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. AIDS Res Hum Retroviruses 2014; 30(12):1162–1169.
   PubMed Web of Science ®Google Scholar
• Lee FJ, Amin J, Bloch M, Pett SL, Marriott D, Carr A. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults. J Acquir Immune Defic Syndr. 2013; 62(5):525–533.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Wu K, Koletar SL, et al. Association between frailty and components of the frailty phenotype with modifiable risk factors and antiretroviral therapy. J Infect Dis. 2017; 215(6):933–937.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Plankey MW, Springer G, et al. Fall frequency and associated factors among men and women with or at risk for HIV infection. HIV Med. 2016; 17(10):740–748.
   Web of Science ®Google Scholar
• Stokes IA, Gardner-Morse MG, Henry SM. Abdominal muscle activation increases lumbar spinal stability: analysis of contributions of different muscle groups. Clin Biomech (Bristol, Avon). 2011; 26(8):797–803.
   PubMed Web of Science ®Google Scholar
• Panjabi MM. The stabilizing system of the spine. Part I. Function, dysfunction, adaptation, and enhancement. J Spinal Disord. 1992; 5(4):383–389; discussion 97.
   PubMedGoogle Scholar
• Cleary LC, Crofford LJ, Long D, et al. Does computed tomography-based muscle density predict muscle function and health-related quality of life in patients with idiopathic inflammatory myopathies? Arthritis Care Res. 2015; 67(7):1031–1040.
   Web of Science ®Google Scholar